mercoledì 21 ottobre 2015

Horizon 2020: i nuovi bandi 2016-17 (NMBP)

Confindustria Ancona 21st October 2015


All’interno del ciclo di incontri “R&I: Diamo credito alla ricerca”, il Desk Europa di Confindustria Ancona propone, in collaborazione con l'Agenzia Per la Ricerca Europea (APRE), un incontro sui nuovi bandi 2016-2017 del programma europeo per la ricerca e l'innovazione, Horizon2020, sulla tematica relativa a nanotecnologie, materiali avanzati, biotecnologie, manifatturiero avanzato e processi (NMBP).


Program:

15:30 Registration
16:00 Greetings
Claudio Schiavoni, President of Confindustria Ancona

16:10 Presentation of the first results of Horizon 2020
Elisabetta Giromini, Desk Europe di Confindustria Ancona

16:25 Presentation of new work programs and for the telematics NMBP
Serena Borgna, APRE

17:10 Testimony winning company PMI Instrument Phase 2
Oliva Alberti, AD Diatech Pharmacogenetics17:30 Practical advice by an evaluator of projects Horizon2020

Cristina Cristalli, Head R&D Loccioni

17:50 Q&A

For more information please contact: Elisabetta Giromini, Tel.: +39 071 29048225;

martedì 6 ottobre 2015

Giornata nazionale di lancio dei bandi 2016-17 Horizon 2020

 6th October 2015, Sapienza University, Aula Magna, Piazzale Aldo Moro, 5 Rome

Oliva Alberti, CEO Diatech Pharmacogenetics participated as a speaker  during the section 2:

"Sessione 2 “Tavola rotonda sulle esperienze di coordinamento e di valutazione nei ban- di “health, demographic change and well-being, 2014-2015” (14:30 – 16:30)"

Download here the complete presentation.


mercoledì 1 luglio 2015

Horizon 2020 Project LEONID Lung cancEr fusiOn geNes: a new dIagnostic Device




The main scope of LEONID project is the development and validation of the clinical performance of a new diagnostic Nanostring-based device against existing standards (FISH and IHC) for the detection of in vitro biomarkers with predictive power of response to tyrosin kinase inhibitors used for lung cancer treatment.
The device will be the first CE-IVD kit that detects all ALK, ROS1 and RET rearrangements with known and unknown partners in one multiplex assay and that, at the same time, identify the main variants of EML4-ALK.
The clinical validation will be extended to the associated software for secondary analysis of data that will guarantee the results standardization, avoiding any personal interpretation. The new diagnostic device-software combination, that passed the technical feasibility analysis and is ready for experimental verification, will be the easiest, cheapest, fastest and standardized solution for ALK, ROS1 and RET fusions detection without losing sensitivity, specificity, robustness and reproducibility.
The end users will be all molecular pathology laboratories supporting hospitals where lung cancer patients are treated, that (are going to) perform the analysis of fusion genes and want to reduce hands-on-time, error rate, and costs, saving specialized technical expertise and increasing the throughput of biomarkers and samples. At least 85 European medium-high throughput labs running 450 lung samples per year can be considered as potential customers.
For Diatech Pharmacogenetics, the new device will be complementary to the existing products for pharmacogenetics analysis in oncology and will boost the company’s approach of potential European distributors. GeneticLab can offer the test to low throughput labs and can speed up the entrance into the oncology business. BiMind can extend the panel of features of its proprietary oncology EHR dedicated to the analysis of laboratory tests’ results and can provide its new software through Diatech PGx or directly.

Project reference: 673953 

venerdì 27 marzo 2015

Da "Horizon 2020" 1,7 milioni a Diatech per i test anti-cancro

Press review Il Sole 24 Ore 27th March 2015